Search results
Debate over property tax millage reduction for OCCOA continues
Gannett via AOL· 4 days agoIn the fourth quarter last year, the advocacy department had over 1,100 appointments and 800 of...
'It's very frustrating': local voters talk about challenges with rising healthcare costs
TMJ4 Milwaukee· 6 days agoTaking care of their medical bills is impacting their healthcare, from deductibles to premiums....
HHS Updates Regulations Implementing Section 504 of the Rehabilitation Act | JD Supra
JD Supra· 4 days agoOn May 9, 2024, the Biden Administration continued its push to update and modernize federal nondiscrimination protections by publishing revised regulations (the “Final Rule”) that amend the ...
BMO maintains price target on Gilead stock amid oncology push By Investing.com
Investing.com· 4 days agoOn Thursday, BMO Capital Markets sustained its positive stance on Gilead Sciences (NASDAQ:GILD),...
Easier Access to Pot May Revolutionize Health Care for Seniors
Newsweek· 5 days agoOver the next four years, more people in the United States will turn 65 annually than ever...
The ACA 1557 Final Regulations: Plans and Plan Sponsors as Covered Entities
The National Law Review· 6 days agoIn a recent On the Subject (available here), we reported on the impact of the final rule (final...
Unveiling Centene (CNC)'s Value: Is It Really Priced Right? A Co
Guru Focus· 9 hours agoCentene Corp (CNC, Financial) has recently experienced a notable daily loss of 3.49%, contributing to a three-month decline of 6.97%. This analysis delves into whether Centene, currently priced ...
eHealth, Inc. (NASDAQ:EHTH) Shares Sold by Panagora Asset Management Inc.
ETF DAILY NEWS· 2 days agoPanagora Asset Management Inc. cut its stake in eHealth, Inc. (NASDAQ:EHTH – Free Report) by 59.2% in the fourth quarter, according to its most recent 13F filing with the Securities & Exchange ...
FDA signals potential shift toward interchangeability for all biosimilars | JD Supra
JD Supra· 4 days agoUnder the Biologics Price Competition and Innovation Act (BPCIA), a “biosimilar” product is one that is demonstrated to be “highly similar” to the reference product with “no clinically meaningful ...